Blackstone Sells Japanese Drugmaker Alinamin Pharmaceutical to MBK Partners for $2.17 Billion

189

Blackstone (BX.N) and MBK Partners announced that the U.S. private equity firm is selling Japanese drugmaker Alinamin Pharmaceutical to the North Asian buyout fund, MBK Partners. The deal size is expected to be 350 billion yen ($2.17 billion), according to a source who disclosed the information on Tuesday. However, neither Blackstone nor MBK provided specific transaction values in their respective statements.

Blackstone initially acquired Alinamin Pharmaceutical in 2020 from Takeda Pharmaceutical (4502.T), marking what was described as the largest healthcare transaction in Japan at the time. This strategic acquisition was part of Blackstone’s broader investment strategy to expand its footprint in the Asian healthcare market.

In a move that demonstrates continued confidence in Alinamin’s growth potential, Blackstone announced that it will re-invest an indirect, minority stake in the pharmaceutical company upon the closing of the transaction. This reinvestment highlights Blackstone’s commitment to Alinamin’s future and its strategic importance in the region.

The transaction is set to close in the coming months, pending regulatory approvals and customary closing conditions. This acquisition by MBK Partners underscores the growing interest of private equity firms in the Japanese healthcare sector, which is seen as a lucrative market due to its advanced medical infrastructure and aging population.

Alinamin Pharmaceutical has been a significant player in Japan’s healthcare industry, known for its development and distribution of vitamin supplements and other pharmaceutical products. The company’s strong market presence and robust product portfolio have made it an attractive acquisition target for MBK Partners, which aims to further expand its investments in the healthcare sector across North Asia.

This sale is part of Blackstone’s strategy to monetize some of its investments while continuing to support the companies in which it sees long-term growth potential. By maintaining a minority stake in Alinamin, Blackstone can still influence the company’s strategic direction and benefit from its future success.

The currency conversion rate for this transaction is $1 = 161.5100 yen, indicating the substantial financial scale of the deal. This transaction not only represents a significant movement within the private equity landscape but also reflects the ongoing consolidation in the pharmaceutical industry, particularly in Japan.

As the healthcare industry continues to evolve, such strategic investments and acquisitions are expected to play a crucial role in shaping the future landscape. Both Blackstone and MBK Partners are poised to leverage their expertise and resources to drive further growth and innovation within Alinamin Pharmaceutical.

This announcement follows a series of high-profile transactions in the healthcare sector, underscoring the sector’s resilience and attractiveness to investors even amid global economic uncertainties. The deal is anticipated to close smoothly, given the strong track records of both Blackstone and MBK Partners in executing large-scale transactions.

In summary, the sale of Alinamin Pharmaceutical from Blackstone to MBK Partners for $2.17 billion marks a significant development in the Japanese healthcare industry. The reinvestment by Blackstone in a minority stake further emphasizes the potential and strategic importance of Alinamin Pharmaceutical in the regional market.